1. Fey, MF, Buske, C ESMO Guidelines Working Group . Acute myeloblastic leukaemias in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl. 6): vi138–vi143.
Google Scholar | Crossref | Medline2. SEER stat fact sheets: acute myeloid leukemia (AML) . National Cancer Institute, https://seer.cancer.gov/statfacts/index.html (accessed 6 February 2021).
Google Scholar3. Forman, SJ, Rowe, JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077–1082.
Google Scholar | Crossref | Medline | ISI4. Ram, R, Gatt, M, Merkel, D, et al. Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation – a retrospective national multicenter study. Ann Hematol 2017; 96: 575–579.
Google Scholar | Crossref | Medline5. Seymour, JF, Dohner, H, Butrym, A, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer 2017; 17: 852.
Google Scholar | Crossref | Medline6. DiNardo, CD, Stein, EM, de Botton, S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018; 378: 2386–2398.
Google Scholar | Crossref | Medline7. Stein, EM, DiNardo, CD, Fathi, AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019; 133: 676–687.
Google Scholar | Crossref | Medline8. Pratz, KW, Cherry, M, Altman, JK, et al. Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood 2018; 132(Suppl. 1): 564–564.
Google Scholar | Crossref9. Konopleva, M, Pollyea, DA, Potluri, J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 2016; 6: 1106–1117.
Google Scholar | Crossref | Medline10. Kumar, S, Kaufman, JL, Gasparetto, C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017; 130: 2401–2409.
Google Scholar | Crossref | Medline11. Roberts, AW, Davids, MS, Pagel, JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311–322.
Google Scholar | Crossref | Medline | ISI12. Konopleva, M, Contractor, R, Tsao, T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388.
Google Scholar | Crossref | Medline | ISI13. Bogenberger, JM, Kornblau, SM, Pierceall, WE, et al. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014; 28: 1657–1665.
Google Scholar | Crossref | Medline14. DiNardo, CD, Pratz, K, Pullarkat, V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133: 7–17.
Google Scholar | Crossref | Medline15. DiNardo, CD, Jonas, BA, Pullarkat, V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383: 617–629.
Google Scholar | Crossref | Medline16. Cancer stat facts: acute myeloid leukemia . Surveillance, Epidemiology, and End Results Program, https://seer.cancer.gov/statfacts/html/amyl.html (accessed 2 December 2020).
Google Scholar17. Aldoss, I, Yang, D, Aribi, A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica 2018; 103: e404–e407.
Google Scholar | Crossref18. DiNardo, CD, Rausch, CR, Benton, C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018; 93: 401–407.
Google Scholar | Crossref | Medline19. Aldoss, I, Yang, D, Pillai, R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol 2019; 94: E253–E255.
Google Scholar | Crossref20. Aldoss, I, Zhang, J, Pillai, R, et al. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. Br J Haematol 2019; 187: e45–e48.
Google Scholar | Crossref | Medline21. Asghari, H, Lee, D, Deutsch, YE, et al. Outcomes of patients with relapsed or refractory acute myeloid leukemia receiving hypomethylating agent and venetoclax. Blood 2019; 134(Suppl. 1): 1357–1357.
Google Scholar | Crossref22. Mittal, V, Lo, M, Damon, LE, et al. Efficacy of venetoclax combination therapy with hypomethylating agents in patients with relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Blood 2019; 134(Suppl. 1): 5089–5089.
Google Scholar | Crossref23. Ram, R, Amit, O, Zuckerman, T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol 2019; 98: 1927–1932.
Google Scholar | Crossref | Medline24. Aldoss, I, Zhang, J, Mei, M, et al. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. Epub ahead of print 6 July 2020. DOI: 10.1002/ajh.25929.
Google Scholar | Crossref25. Byrne, M, Danielson, N, Sengsayadeth, S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol 2020; 95: 1006–1014.
Google Scholar | Crossref | Medline26. DiNardo, CD, Maiti, A, Rausch, CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 2020; 7: e724–e736.
Google Scholar | Crossref | Medline27. Gaut, D, Burkenroad, A, Duong, T, et al. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: a single institution experience. Leuk Res 2020; 90: 106314.
Google Scholar | Crossref | Medline28. Lou, Y, Shao, L, Mao, L, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res 2020; 91: 106317.
Google Scholar | Crossref | Medline29. Morsia, E, McCullough, K, Joshi, M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol 2020; 95: 1511–1521.
Google Scholar | Crossref | Medline30. Tiong, IS, Dillon, R, Ivey, A, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol 2021; 192: 1026–1030.
Google Scholar | Crossref | Medline31. Wang, YW, Tsai, CH, Lin, CC, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol 2020; 99: 501–511.
Google Scholar | Crossref | Medline32. Winters, AC, Maloney, KW, Treece, AL, et al. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer 2020; 67: e28398.
Google Scholar | Crossref | Medline33. Joshi, M, Cook, J, McCullough, K, et al. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021; 11: 49.
Google Scholar | Crossref | Medline34. Coccia, PF, Altman, J, Bhatia, S, et al. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2012; 10: 1112–1150.
Google Scholar | Crossref | Medline | ISI35. Dohner, H, Weisdorf, DJ, Bloomfield, CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152.
Google Scholar | Crossref | Medline | ISI36. Rowe, JM, Tallman, MS. How I treat acute myeloid leukemia. Blood 2010; 116: 3147–3156.
Google Scholar | Crossref | Medline37. Menzin, J, Lang, K, Earle, CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 1597–1603.
Google Scholar | Crossref | Medline38. Mohammadi, M, Cao, Y, Glimelius, I, et al. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population based study. BMC Cancer 2015; 15: 850.
Google Scholar | Crossref | Medline39. Sandhu, KS, Dadwal, S, Yang, D, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant 2020; 26: e322–e327.
Google Scholar | Crossref | Medline40. Aldoss, I, Dadwal, S, Zhang, J, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv 2019; 3: 4043–4049.
Google Scholar | Crossref | Medline41. DiNardo, CD, Pratz, KW, Letai, A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19: 216–228.
Google Scholar | Crossref | Medline42. Mei, M, Aldoss, I, Marcucci, G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 2019; 94: 358–362.
Google Scholar | Medline43. Bose, P, McCue, D, Wurster, S, et al. Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study. Clin Infect Dis 2021; 72: 1755–1763.
Google Scholar | Crossref | Medline44. Rausch, CR, DiNardo, CD, Maiti, A, et al. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 2021; 127: 2489–2499.
Google Scholar | Crossref | Medline45. Bergua, JM, Montesinos, P, Martinez-Cuadrón, D, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol 2016; 174: 700–710.
Google Scholar | Crossref | Medline46. Short, NJ, Montalban-Bravo, G, Hwang, H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 2020; 4: 5681–5689.
Google Scholar | Crossref | Medline